Biogen gets EU court ruling in favor of blocking Tecfidera generic entry

Biogen (NASDAQ:BIIB) said that the Court of Justice of the EU decided in favor of the company, the European Medicines Agency (EMA), and the European Commission (EC) in their appeal of a General Court decision annulling the EMA's refusal to evaluate a generic version of multiple sclerosis drug Tecfidera.